FDA Inspection 771895 — Northern Indiana Cancer Research Consortium IRB

Northern Indiana Cancer Research Consortium IRB — FEI 3009194999

The FDA completed an inspection of Northern Indiana Cancer Research Consortium IRB on February 21, 2012 in South Bend, IN. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). 2 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Official Action Indicated (OAI) (OAI)
End Date
February 21, 2012
Fiscal Year
2012
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
South Bend, IN (United States)

Additional Details

IRB

Citations

IDCFRDescription
728121 CFR 56.108(a)(1)Initial and continuing reviews
731821 CFR 56.115(a)(2)Minutes of IRB meetings